Preeclampsia Ratio (sFlt-1/PlGF)

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 20, 2017

Keywords

ClinConnect Summary

Preeclampsia is a hypertensive disorder of pregnancy associated with placental insufficiency and is one of the major important of prematurity and maternal mortality worldwide. It complicates 2 to 7% of pregnancies. It is currently considered that preeclampsia is associated with maternal endothelial dysfunction induced by the release into the maternal circulation of excess placental factors (such as sFLT-1 a soluble receptor for VEGF and PlGF). There is currently no curative treatment, and only childbirth and delivery of the placenta alleviate the mother's symptoms. Moreover, the evolution f...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patient hospitalized for suspected preeclampsia between 24WG+ 0 days and 35WG + 6 days,
• Patiente with at least one of the following criteria:
• • Arterial hypertension defined by systolic BP ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg
• • Proteinuria greater than 0.3g / 24h or 0.3g / l or ≥ 3+
• • Proteinuria / creatinine ratio ≥ 30 mg / mmol
• • Pain in the epigastric bar
• • Generalized edema
• • Hepatic cytolysis\> 1.5N
• • Thrombocytopenia \<150000 / mm3 Informed consent signed by both parties Non-opposition was accepted by parental authority Age ≥ 18 years
• Exclusion Criteria:
• • Diagnosis of preeclampsia (arterial pressure\> 140/90 and proteinuria\> 0.3g / 24h or urine test\> 3+) or complete HELLP syndrome (Platelets \<100000 / mm3 and SGOT\> 2N and LDH and collapsed Haptoglobin)
• • IUGR with absent or reverse diastolic umbilical flow
• • Fetal heart rate abnormalities
• • Gestational age \<24 WG and\> 35 WG
• • Multiple pregnancy
• • Patient without health insurance
• • Non-consent of patient
• • Minor patient
• • Congenital malformation